on (#3Y8DS)
Delamanid, a nitro-imidazole, is a new tuberculosis (TB) drug developed to address some of the adverse reactions and related adherence difficulties associated with currently available mediations for treating drug-resistant TB. A patient with extensively drug-resistant TB was successfully treated in 2017.